Dr. Hwang on the Utility of Docetaxel in mCSPC

Video

Clara Hwang, MD, discusses the utility of docetaxel and abiraterone acetate in metastatic castration-sensitive prostate cancer.

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses the utility of docetaxel in metastatic castration-sensitive prostate cancer (mCSPC).

Two trials examined docetaxel in the mCSPC space: CHAARTED and STAMPEDE, says Hwang. The multiarm, phase 3 STAMPEDE trial examined the addition of up-front abiraterone acetate (Zytiga) or doctaxel to androgen deprivation therapy (ADT). The study was conducted in the United Kingdom and has answered several questions in this space, says Hwang. In the CHAARTED study, investigators wanted to see whether concomitant treatment of docetaxel with ADT would result in longer overall survival than ADT alone. Both trials showed that docetaxel improved survival for patients with mCSPC, says Hwang.

Data with abiraterone acetate were also reported; results from STAMPEDE and the LATITUDE trial showed that the addition of abiraterone to standard of care, which at the time was ADT, also improved survival in this patient population, concludes Hwang.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD